DOCSLIB.ORG

2012 Case Definitions Infectious Disease

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2012 Case Definitions Infectious Disease Arizona Department of Health Services Case Definitions for Reportable Communicable Morbidities 2012 TABLE OF CONTENTS Definition of Terms Used in Case Classification .......................................................................................................... 6 Definition of Bi-national Case ............................................................................................................................................. 7 ------------------------------------------------------------------------------------------------------- ............................................... 7 AMEBIASIS ............................................................................................................................................................................. 8 ANTHRAX (β) ......................................................................................................................................................................... 9 ASEPTIC MENINGITIS (viral) ......................................................................................................................................... 11 BASIDIOBOLOMYCOSIS ................................................................................................................................................. 12 BOTULISM, FOODBORNE (β) ....................................................................................................................................... 13 BOTULISM, INFANT (β) .................................................................................................................................................... 14 BOTULISM, WOUND (β) ................................................................................................................................................... 15 BOTULISM, OTHER (β) .................................................................................................................................................... 16 BRUCELLOSIS (β) .............................................................................................................................................................. 17 BURKHOLDERIA MALLEI and B. PSEUDOMALLEI ............................................................................................... 18 CAMPYLOBACTERIOSIS ................................................................................................................................................ 19 CHAGAS DISEASE ............................................................................................................................................................ 20 CHANCROID......................................................................................................................................................................... 21 CHLAMYDIA TRACHOMATIS INFECTION ................................................................................................................ 22 CHOLERA (β) ....................................................................................................................................................................... 24 COCCIDIOIDOMYCOSIS (Valley fever) ...................................................................................................................... 25 COLORADO TICK FEVER ............................................................................................................................................... 26 CONJUNCTIVITIS, ACUTE .............................................................................................................................................. 27 CREUTZFELDT-JAKOB DISEASE................................................................................................................................ 28 CRYPTOSPORIDIOSIS (Cryptosporidium parvum) ................................................................................................. 30 CYCLOSPORAISIS ............................................................................................................................................................ 32 CYSTICERCOSIS ............................................................................................................................................................... 33 DENGUE FEVER (β) .......................................................................................................................................................... 34 DIARRHEA, NAUSEA, OR VOMITING ........................................................................................................................ 36 DIPHTHERIA (β) .................................................................................................................................................................. 37 EHRLICHIOSIS / ANAPLASMOSIS .............................................................................................................................. 39 EMERGING OR EXOTIC DISEASE .............................................................................................................................. 42 ENCEPHALITIS, VIRAL or PARASITIC ....................................................................................................................... 43 ENTEROHEMORRHAGIC ESCHERICHIA COLI ..................................................................................................... 45 ENTEROTOXIGENIC ESCHERICHIA COLI (ETEC)............................................................................................... 47 FOODBORNE DISEASE OUTBREAK ......................................................................................................................... 48 GIARDIASIS .......................................................................................................................................................................... 49 GONORRHEA ...................................................................................................................................................................... 51 HAEMOPHILUS INFLUENZAE ....................................................................................................................................... 52 HANSEN’S DISEASE (LEPROSY) ................................................................................................................................ 53 HANTAVIRUS ....................................................................................................................................................................... 54 HEMOLYTIC UREMIC SYNDROME ............................................................................................................................. 56 HEPATITIS A (β) .................................................................................................................................................................. 58 HEPATITIS B, ACUTE (ß) ................................................................................................................................................ 59 HEPATITIS B, CHRONIC ................................................................................................................................................. 61 HEPATITIS B, PERINATAL- Acquired in the United States or U.S. Territories ............................................... 63 HEPATITIS C, ACUTE (β) ................................................................................................................................................ 64 HEPATITIS C, CHRONIC or past infection ................................................................................................................. 65 HEPATITIS D ........................................................................................................................................................................ 67 HEPATITIS E ........................................................................................................................................................................ 68 HERPES GENITALIS ......................................................................................................................................................... 69 HUMAN IMMUNODEFICIENCY VIRUS (HIV) (β)..................................................................................................... 73 2 ADHS Communicable Disease Case Definitions MARCH 2011 INFLUENZA ........................................................................................................................................................................... 77 INFLUENZA-ASSOCIATED PEDIATRIC MORTALITY .......................................................................................... 78 KAWASAKI SYNDROME .................................................................................................................................................. 79 LEGIONELLOSIS (Legionnaires’ disease) .................................................................................................................. 80 LEPTOSPIROSIS ................................................................................................................................................................ 82 LISTERIOSIS (Listeria monocytogenes) ...................................................................................................................... 83 LYME DISEASE ..................................................................................................................................................................
Load more

Recommended publications
  • Reporting of Diseases and Conditions Regulation, Amendment, M.R. 289/2014
    THE PUBLIC HEALTH ACT LOI SUR LA SANTÉ PUBLIQUE (C.C.S.M. c. P210) (c. P210 de la C.P.L.M.) Reporting of Diseases and Conditions Règlement modifiant le Règlement sur la Regulation, amendment déclaration de maladies et d'affections Regulation 289/2014 Règlement 289/2014 Registered December 23, 2014 Date d'enregistrement : le 23 décembre 2014 Manitoba Regulation 37/2009 amended Modification du R.M. 37/2009 1 The Reporting of Diseases and 1 Le présent règlement modifie le Conditions Regulation , Manitoba Règlement sur la déclaration de maladies et Regulation 37/2009, is amended by this d'affections , R.M. 37/2009. regulation. 2 Schedules A and B are replaced with 2 Les annexes A et B sont remplacées Schedules A and B to this regulation. par les annexes A et B du présent règlement. Coming into force Entrée en vigueur 3 This regulation comes into force on 3 Le présent règlement entre en vigueur January 1, 2015, or on the day it is registered le 1 er janvier 2015 ou à la date de son under The Statutes and Regulations Act , enregistrement en vertu de Loi sur les textes whichever is later. législatifs et réglementaires , si cette date est postérieure. December 19, 2014 Minister of Health/La ministre de la Santé, 19 décembre 2014 Sharon Blady 1 SCHEDULE A (Section 1) 1 The following diseases are diseases requiring contact notification in accordance with the disease-specific protocol. Common name Scientific or technical name of disease or its infectious agent Chancroid Haemophilus ducreyi Chlamydia Chlamydia trachomatis (including Lymphogranuloma venereum (LGV) serovars) Gonorrhea Neisseria gonorrhoeae HIV Human immunodeficiency virus Syphilis Treponema pallidum subspecies pallidum Tuberculosis Mycobacterium tuberculosis Mycobacterium africanum Mycobacterium canetti Mycobacterium caprae Mycobacterium microti Mycobacterium pinnipedii Mycobacterium bovis (excluding M.
    [Show full text]
  • Ocular Leishmaniasis Presenting As Chronic
    perim Ex en l & ta a l ic O p in l h t C h f Journal of Clinical & Experimental a o l m l a o n l r o g u Ayele et al., J Clin Exp Ophthalmol 2015, 6:1 y o J Ophthalmology ISSN: 2155-9570 DOI: 10.4172/2155-9570.1000395 Case Report Open Access Ocular Leishmaniasis Presenting as Chronic Ulcerative Blepharoconjunctivitis: A Case Report Fisseha Admassu Ayele*, Yared Assefa Wolde, Tesfalem Hagos and Ermias Diro University of Gondar, Gondar, Amhara, Ethiopia *Corresponding author: Fisseha Admassu Ayele MD, University of Gondar, Gondar, Amhara 196, Ethiopia, Tel: 251911197786; E-mail: [email protected] Received date: Dec 01, 2014, Accepted date: Feb 02, 2015, Published date: Feb 05, 2015 Copyright: © 2015 Ayele FH, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Leishmaniasis is caused by unicellular eukaryotic obligate intracellular protozoa of the genus Leishmania that is endemic in over 98 countries in the world-most of which are developing countries including Ethiopia. It is transmitted by phlebotomine sandflies. The eye may be affected in cutaneous, mucocutaneous and Post Kala-Azar Dermal Leishmaniasis. We report a case of ocular leishmaniasis with eyelid and conjunctival involvement that had simulated ulcerative blepharoconjunctivitis not responding to conventional antibiotics. The patient was diagnosed by microscopy of a sample obtained via direct smear from the lesions. He was treated with systemic sodium stibogluconate (20 mg/kg/day) for 45 days and was clinically cured with this treatment.
    [Show full text]
  • Sexually Transmitted Disease (STD) Case Definitions (Source: Centers for Disease Control and Prevention
    Sexually Transmitted Disease (STD) Case Definitions (Source: Centers for Disease Control and Prevention. Case definitions for infectious conditions under public health surveillance, 1997. MMWR Morb Mortal Wkly Rep. 1997;46(No. RR-10).) STD Conditions Reportable in Arizona Chancroid (Revised 9/96) Clinical description A sexually transmitted disease characterized by painful genital ulceration and inflammatory inguinal adenopathy. The disease is caused by infection with Haemophilus ducreyi. Laboratory criteria for diagnosis Isolation of H. ducreyi from a clinical specimen Case classification Probable: a clinically compatible case with both a) no evidence of Treponema pallidum infection by darkfield microscopic examination of ulcer exudate or by a serologic test for syphilis performed ≥7 days after onset of ulcers and b) either a clinical presentation of the ulcer(s) not typical of disease caused by herpes simplex virus (HSV) or a culture negative for HSV. Confirmed: a clinically compatible case that is laboratory confirmed Chlamydia Infection (Revised 6/09) Clinical description Infection with Chlamydia trachomatis may result in urethritis, epididymitis, cervicitis, acute salpingitis, or other syndromes when sexually transmitted; however, the infection is often asymptomatic in women. Perinatal infections may result in inclusion conjunctivitis and pneumonia in newborns. Other syndromes caused by C. trachomatis include lymphogranuloma venereum (see Lymphogranuloma Venereum) and trachoma. Laboratory criteria for diagnosis Isolation of C. trachomatis
    [Show full text]
  • Are You Suprised ?
    B DAMB 721 Microbiology Final Exam B 100 points December 11, 2006 Your name (Print Clearly): _____________________________________________ I. Matching: The questions below consist of headings followed by a list of phrases. For each phrase select the heading that best describes that phrase. The headings may be used once, more than once or not at all. Mark the answer in Part 2 of your answer sheet. 1. capsid 7. CD4 2. Chlamydia pneumoniae 8. Enterococcus faecalis 3. oncogenic 9. hyaluronidase 4. pyruvate 10. interferon 5. Koplik’s spot 11. hydrophilic viruses 6. congenital Treponema pallidum 12. Streptococcus pyogenes 1. “spreading factor” produced by members of the staphylococci, streptococci and clostridia 2. viral protein coat 3. central intermediate in bacterial fermentation 4. persistant endodontic infections 5. a cause of atypical pneumonia 6. nonspecific defense against viral infection 7. has a rudimentary life cycle 8. HIV receptor 9. Hutchinson’s Triad 10. measles 11. resistant to disinfection 12. β-hemolytic, bacitracin sensitive, cause of suppurative pharyngitis 2 Matching (Continued): The questions below consist of diseases followed by a list of etiologic agents. Match each disease with the etiologic agent. Continue using Part 2 of your answer sheet. 1. dysentery 6. Legionnaire’s 2. botulism 7. gas gangrene 3. cholera 8. tuberculosis 4. diphtheria 9. necrotizing fascitis 5. enteric fever 10. pneumoniae/meningitis 13. Clostridium botulinum 14. Vibrio cholera 15. Mycobacterium bovis 16. Shigella species 17. Streptococcus pneumoniae 18. Clostridium perfringens 19. Salmonella typhi 20. Streptococcus pyogenes 3 II. Multiple Choice: Choose the ONE BEST answer. Mark the correct answer on Part 1 of the answer sheet.
    [Show full text]
  • Parinaud's Oculoglandular Syndrome
    Tropical Medicine and Infectious Disease Case Report Parinaud’s Oculoglandular Syndrome: A Case in an Adult with Flea-Borne Typhus and a Review M. Kevin Dixon 1, Christopher L. Dayton 2 and Gregory M. Anstead 3,4,* 1 Baylor Scott & White Clinic, 800 Scott & White Drive, College Station, TX 77845, USA; [email protected] 2 Division of Critical Care, Department of Medicine, University of Texas Health, San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA; [email protected] 3 Medical Service, South Texas Veterans Health Care System, San Antonio, TX 78229, USA 4 Division of Infectious Diseases, Department of Medicine, University of Texas Health, San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA * Correspondence: [email protected]; Tel.: +1-210-567-4666; Fax: +1-210-567-4670 Received: 7 June 2020; Accepted: 24 July 2020; Published: 29 July 2020 Abstract: Parinaud’s oculoglandular syndrome (POGS) is defined as unilateral granulomatous conjunctivitis and facial lymphadenopathy. The aims of the current study are to describe a case of POGS with uveitis due to flea-borne typhus (FBT) and to present a diagnostic and therapeutic approach to POGS. The patient, a 38-year old man, presented with persistent unilateral eye pain, fever, rash, preauricular and submandibular lymphadenopathy, and laboratory findings of FBT: hyponatremia, elevated transaminase and lactate dehydrogenase levels, thrombocytopenia, and hypoalbuminemia. His condition rapidly improved after starting doxycycline. Soon after hospitalization, he was diagnosed with uveitis, which responded to topical prednisolone. To derive a diagnostic and empiric therapeutic approach to POGS, we reviewed the cases of POGS from its various causes since 1976 to discern epidemiologic clues and determine successful diagnostic techniques and therapies; we found multiple cases due to cat scratch disease (CSD; due to Bartonella henselae) (twelve), tularemia (ten), sporotrichosis (three), Rickettsia conorii (three), R.
    [Show full text]
  • (Tea Tree) Oil and Dimethyl Sulfoxide (DMSO) Against Trophozoites and Cysts of Acanthamoeba Strains
    pathogens Article In Vitro Evaluation of the Combination of Melaleuca alternifolia (Tea Tree) Oil and Dimethyl Sulfoxide (DMSO) against Trophozoites and Cysts of Acanthamoeba Strains. Oxygen Consumption Rate (OCR) Assay as a Method for Drug Screening Tania Martín-Pérez *, Irene Heredero-Bermejo , Cristina Verdú-Expósito and Jorge Pérez-Serrano Department of Biomedicine and Biotechnology, Faculty of Pharmacy, University of Alcalá, Alcalá de Henares, 28805 Madrid, Spain; [email protected] (I.H.-B.); [email protected] (C.V.-E.); [email protected] (J.P.-S.) * Correspondence: [email protected] Abstract: Ameobae belonging to the genus Acanthamoeba are responsible for the human diseases Acanthamoeba keratitis (AK) and granulomatous amoebic encephalitis (GAE). The treatment of these illnesses is hampered by the existence of a resistance stage (cysts). In an attempt to add new agents that are effective against trophozoites and cysts, tea tree oil (TTO) and dimethyl sulfoxide (DMSO), separately and in combination, were tested In Vitro against two Acanthamoeba isolates, Citation: Martín-Pérez, T.; T3 and T4 genotypes. The oxygen consumption rate (OCR) assay was used as a drug screening Heredero-Bermejo, I.; Verdú-Expósito, method, which is to some extent useful in amoebicide drug screening; however, evaluation of lethal C.; Pérez-Serrano, J. In Vitro effects may be misleading when testing products that promote encystment. Trophozoite viability Evaluation of the Combination of analysis showed that the effectiveness of the combination of both compounds is higher than when Melaleuca alternifolia (Tea Tree) Oil either compound is used alone. Therefore, the TTO alone or TTO + DMSO in combination were and Dimethyl Sulfoxide (DMSO) against Trophozoites and Cysts of an amoebicide, but most of the amoebicidal activity in the combination’s treatments seemed to be Acanthamoeba Strains.
    [Show full text]
  • Syphilis Staging and Treatment Syphilis Is a Sexually Transmitted Disease (STD) Caused by the Treponema Pallidum Bacterium
    Increasing Early Syphilis Cases in Illinois – Syphilis Staging and Treatment Syphilis is a sexually transmitted disease (STD) caused by the Treponema pallidum bacterium. Syphilis can be separated into four different stages: primary, secondary, early latent, and late latent. Ocular and neurologic involvement may occur during any stage of syphilis. During the incubation period (time from exposure to clinical onset) there are no signs or symptoms of syphilis, and the individual is not infectious. Incubation can last from 10 to 90 days with an average incubation period of 21 days. During this period, the serologic testing for syphilis will be non-reactive but known contacts to early syphilis (that have been exposed within the past 90 days) should be preventatively treated. Syphilis Stages Primary 710 (CDC DX Code) Patient is most infectious Chancre (sore) must be present. It is usually marked by the appearance of a single sore, but multiple sores are common. Chancre appears at the spot where syphilis entered the body and is usually firm, round, small, and painless. The chancre lasts three to six weeks and will heal without treatment. Without medical attention the infection progresses to the secondary stage. Secondary 720 Patient is infectious This stage typically begins with a skin rash and mucous membrane lesions. The rash may manifest as rough, red, or reddish brown spots on the palms of the hands, soles of the feet, and/or torso and extremities. The rash does usually does not cause itching. Rashes associated with secondary syphilis can appear as the chancre is healing or several weeks after the chancre has healed.
    [Show full text]
  • Disseminated Mycobacterium Tuberculosis with Ulceronecrotic Cutaneous Disease Presenting As Cellulitis Kelly L
    Lehigh Valley Health Network LVHN Scholarly Works Department of Medicine Disseminated Mycobacterium Tuberculosis with Ulceronecrotic Cutaneous Disease Presenting as Cellulitis Kelly L. Reed DO Lehigh Valley Health Network, [email protected] Nektarios I. Lountzis MD Lehigh Valley Health Network, [email protected] Follow this and additional works at: http://scholarlyworks.lvhn.org/medicine Part of the Dermatology Commons, and the Medical Sciences Commons Published In/Presented At Reed, K., Lountzis, N. (2015, April 24). Disseminated Mycobacterium Tuberculosis with Ulceronecrotic Cutaneous Disease Presenting as Cellulitis. Poster presented at: Atlantic Dermatological Conference, Philadelphia, PA. This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an authorized administrator. For more information, please contact [email protected]. Disseminated Mycobacterium Tuberculosis with Ulceronecrotic Cutaneous Disease Presenting as Cellulitis Kelly L. Reed, DO and Nektarios Lountzis, MD Lehigh Valley Health Network, Allentown, Pennsylvania Case Presentation: Discussion: Patient: 83 year-old Hispanic female Cutaneous tuberculosis (CTB) was first described in the literature in 1826 by Laennec and has since been History of Present Illness: The patient presented to the hospital for chest pain and shortness of breath and was treated for an NSTEMI. She was noted reported to manifest in a variety of clinical presentations. The most common cause is infection with the to have redness and swelling involving the right lower extremity she admitted to having for 5 months, which had not responded to multiple courses of antibiotics. She acid-fast bacillus Mycobacterium tuberculosis via either primary exogenous inoculation (direct implantation resided in Puerto Rico but recently moved to the area to be closer to her children.
    [Show full text]
  • Morbidity and Mortality Weekly Report Weekly March 20, 2009 / Vol
    Morbidity and Mortality Weekly Report www.cdc.gov/mmwr Weekly March 20, 2009 / Vol. 58 / No. 10 Trends in Tuberculosis — World TB Day — March 24, 2009 United States, 2008 World TB Day is observed each year on March 24 to commemorate the date in 1882 when Dr. Robert Koch In 2008, a total of 12,898 incident tuberculosis (TB) cases announced the discovery of Mycobacterium tuberculosis, the were reported in the United States; the TB rate declined 3.8% bacterium that causes tuberculosis (TB). Worldwide, TB from 2007 to 4.2 cases per 100,000 population, the lowest remains one of the leading causes of death from infectious rate recorded since national reporting began in 1953. This disease. An estimated 2 billion persons are infected with report summarizes provisional 2008 data from the National M. tuberculosis (1). In 2006, approximately 9.2 million TB Surveillance System and describes trends since 1993. persons became ill from TB, and 1.7 million died from Despite this overall improvement, progress has slowed in the disease (1). World TB Day provides an opportunity recent years; the average annual percentage decline in the TB for TB programs, nongovernmental organizations, and rate decreased from 7.3% per year during 1993–2000 to 3.8% other partners to describe problems and solutions related during 2000–2008.* Foreign-born persons and racial/ethnic to the TB pandemic and to support worldwide TB minorities continued to bear a disproportionate burden of TB control efforts. The U.S. theme for this year’s observance disease in the United States. In 2008, the TB rate in foreign- is Partnerships for TB Elimination.
    [Show full text]
  • Compendium of Measures to Control Chlamydia Psittaci Infection Among
    Compendium of Measures to Control Chlamydia psittaci Infection Among Humans (Psittacosis) and Pet Birds (Avian Chlamydiosis), 2017 Author(s): Gary Balsamo, DVM, MPH&TMCo-chair Angela M. Maxted, DVM, MS, PhD, Dipl ACVPM Joanne W. Midla, VMD, MPH, Dipl ACVPM Julia M. Murphy, DVM, MS, Dipl ACVPMCo-chair Ron Wohrle, DVM Thomas M. Edling, DVM, MSpVM, MPH (Pet Industry Joint Advisory Council) Pilar H. Fish, DVM (American Association of Zoo Veterinarians) Keven Flammer, DVM, Dipl ABVP (Avian) (Association of Avian Veterinarians) Denise Hyde, PharmD, RP Preeta K. Kutty, MD, MPH Miwako Kobayashi, MD, MPH Bettina Helm, DVM, MPH Brit Oiulfstad, DVM, MPH (Council of State and Territorial Epidemiologists) Branson W. Ritchie, DVM, MS, PhD, Dipl ABVP, Dipl ECZM (Avian) Mary Grace Stobierski, DVM, MPH, Dipl ACVPM (American Veterinary Medical Association Council on Public Health and Regulatory Veterinary Medicine) Karen Ehnert, and DVM, MPVM, Dipl ACVPM (American Veterinary Medical Association Council on Public Health and Regulatory Veterinary Medicine) Thomas N. Tully JrDVM, MS, Dipl ABVP (Avian), Dipl ECZM (Avian) (Association of Avian Veterinarians) Source: Journal of Avian Medicine and Surgery, 31(3):262-282. Published By: Association of Avian Veterinarians https://doi.org/10.1647/217-265 URL: http://www.bioone.org/doi/full/10.1647/217-265 BioOne (www.bioone.org) is a nonprofit, online aggregation of core research in the biological, ecological, and environmental sciences. BioOne provides a sustainable online platform for over 170 journals and books published by nonprofit societies, associations, museums, institutions, and presses. Your use of this PDF, the BioOne Web site, and all posted and associated content indicates your acceptance of BioOne’s Terms of Use, available at www.bioone.org/page/terms_of_use.
    [Show full text]
  • Reportable Diseases and Conditions
    KINGS COUNTY DEPARTMENT of PUBLIC HEALTH 330 CAMPUS DRIVE, HANFORD, CA 93230 REPORTABLE DISEASES AND CONDITIONS Title 17, California Code of Regulations, §2500, requires that known or suspected cases of any of the diseases or conditions listed below are to be reported to the local health jurisdiction within the specified time frame: REPORT IMMEDIATELY BY PHONE During Business Hours: (559) 852-2579 After Hours: (559) 852-2720 for Immediate Reportable Disease and Conditions Anthrax Escherichia coli: Shiga Toxin producing (STEC), Rabies (Specify Human or Animal) Botulism (Specify Infant, Foodborne, Wound, Other) including E. coli O157:H7 Scrombroid Fish Poisoning Brucellosis, Human Flavivirus Infection of Undetermined Species Shiga Toxin (Detected in Feces) Cholera Foodborne Disease (2 or More Cases) Smallpox (Variola) Ciguatera Fish Poisoning Hemolytic Uremic Syndrome Tularemia, human Dengue Virus Infection Influenza, Novel Strains, Human Viral Hemorrhagic Fever (Crimean-Congo, Ebola, Diphtheria Measles (Rubeola) Lassa, and Marburg Viruses) Domonic Acid Poisoning (Amnesic Shellfish Meningococcal Infections Yellow Fever Poisoning) Novel Virus Infection with Pandemic Potential Zika Virus Infection Paralytic Shellfish Poisoning Plague (Specify Human or Animal) Immediately report the occurrence of any unusual disease OR outbreaks of any disease. REPORT BY PHONE, FAX, MAIL WITHIN ONE (1) WORKING DAY Phone: (559) 852-2579 Fax: (559) 589-0482 Mail: 330 Campus Drive, Hanford 93230 Conditions may also be reported electronically via the California
    [Show full text]
  • Diagnostic Code Descriptions (ICD9)
    INFECTIONS AND PARASITIC DISEASES INTESTINAL AND INFECTIOUS DISEASES (001 – 009.3) 001 CHOLERA 001.0 DUE TO VIBRIO CHOLERAE 001.1 DUE TO VIBRIO CHOLERAE EL TOR 001.9 UNSPECIFIED 002 TYPHOID AND PARATYPHOID FEVERS 002.0 TYPHOID FEVER 002.1 PARATYPHOID FEVER 'A' 002.2 PARATYPHOID FEVER 'B' 002.3 PARATYPHOID FEVER 'C' 002.9 PARATYPHOID FEVER, UNSPECIFIED 003 OTHER SALMONELLA INFECTIONS 003.0 SALMONELLA GASTROENTERITIS 003.1 SALMONELLA SEPTICAEMIA 003.2 LOCALIZED SALMONELLA INFECTIONS 003.8 OTHER 003.9 UNSPECIFIED 004 SHIGELLOSIS 004.0 SHIGELLA DYSENTERIAE 004.1 SHIGELLA FLEXNERI 004.2 SHIGELLA BOYDII 004.3 SHIGELLA SONNEI 004.8 OTHER 004.9 UNSPECIFIED 005 OTHER FOOD POISONING (BACTERIAL) 005.0 STAPHYLOCOCCAL FOOD POISONING 005.1 BOTULISM 005.2 FOOD POISONING DUE TO CLOSTRIDIUM PERFRINGENS (CL.WELCHII) 005.3 FOOD POISONING DUE TO OTHER CLOSTRIDIA 005.4 FOOD POISONING DUE TO VIBRIO PARAHAEMOLYTICUS 005.8 OTHER BACTERIAL FOOD POISONING 005.9 FOOD POISONING, UNSPECIFIED 006 AMOEBIASIS 006.0 ACUTE AMOEBIC DYSENTERY WITHOUT MENTION OF ABSCESS 006.1 CHRONIC INTESTINAL AMOEBIASIS WITHOUT MENTION OF ABSCESS 006.2 AMOEBIC NONDYSENTERIC COLITIS 006.3 AMOEBIC LIVER ABSCESS 006.4 AMOEBIC LUNG ABSCESS 006.5 AMOEBIC BRAIN ABSCESS 006.6 AMOEBIC SKIN ULCERATION 006.8 AMOEBIC INFECTION OF OTHER SITES 006.9 AMOEBIASIS, UNSPECIFIED 007 OTHER PROTOZOAL INTESTINAL DISEASES 007.0 BALANTIDIASIS 007.1 GIARDIASIS 007.2 COCCIDIOSIS 007.3 INTESTINAL TRICHOMONIASIS 007.8 OTHER PROTOZOAL INTESTINAL DISEASES 007.9 UNSPECIFIED 008 INTESTINAL INFECTIONS DUE TO OTHER ORGANISMS
    [Show full text]